UNLABELLED: (See the editorial commentary by Morris and Masur, on pages 203-204.) BACKGROUND: Improved noninvasive diagnostic tests for Pneumocystis jirovecii pneumonia (PCP) are needed. We evaluated the test characteristics of plasma (1 → 3)-β-D-glucan (β-glucan) for HIV-related PCP among a large group of patients presenting with diverse opportunistic infections (OIs). METHODS: The study population included all 282 participants in AIDS Clinical Trials Group A5164, a study of early versus deferred antiretroviral therapy in conjunction with initial therapy of acute OIs. Baseline plasma samples were assayed for β-glucan, with standard assay reference values defining ≥ 80 pg/mL as positive. Before this analysis, diagnosis of PCP was independently adjudicated by 2 study investigators after reviewing reports from study sites. RESULTS: A total of 252 persons had a β-glucan result that could be analyzed, 173 (69%) of whom had received a diagnosis of PCP. Median β-glucan with PCP was 408 pg/mL (interquartile range [IQR], 209-500 pg/mL), compared with 37 pg/mL (IQR, 31-235 pg/mL) without PCP (P < .001). The sensitivity of β-glucan dichotomized at 80 pg/mL for the diagnosis of PCP was 92% (95% confidence interval [CI], 87%-96%), and the specificity was 65% (95% CI, 53%-75%); positive and negative predictive values were 85% (95% CI, 79%-90%) and 80% (95% CI, 68%-89%) respectively, based on the study prevalence of 69% of patients with PCP. Rates of abnormal lactate dehyrogenase levels did not differ significantly between those with and without PCP. CONCLUSIONS: Blood (1 → 3)-β-D-glucan is strongly correlated with HIV-related PCP. In some clinical centers, this may be a more sensitive test than the induced sputum examination and could reduce the need for both bronchoscopy and empirical therapy of PCP.
UNLABELLED: (See the editorial commentary by Morris and Masur, on pages 203-204.) BACKGROUND: Improved noninvasive diagnostic tests for Pneumocystis jirovecii pneumonia (PCP) are needed. We evaluated the test characteristics of plasma (1 → 3)-β-D-glucan (β-glucan) for HIV-related PCP among a large group of patients presenting with diverse opportunistic infections (OIs). METHODS: The study population included all 282 participants in AIDS Clinical Trials Group A5164, a study of early versus deferred antiretroviral therapy in conjunction with initial therapy of acute OIs. Baseline plasma samples were assayed for β-glucan, with standard assay reference values defining ≥ 80 pg/mL as positive. Before this analysis, diagnosis of PCP was independently adjudicated by 2 study investigators after reviewing reports from study sites. RESULTS: A total of 252 persons had a β-glucan result that could be analyzed, 173 (69%) of whom had received a diagnosis of PCP. Median β-glucan with PCP was 408 pg/mL (interquartile range [IQR], 209-500 pg/mL), compared with 37 pg/mL (IQR, 31-235 pg/mL) without PCP (P < .001). The sensitivity of β-glucan dichotomized at 80 pg/mL for the diagnosis of PCP was 92% (95% confidence interval [CI], 87%-96%), and the specificity was 65% (95% CI, 53%-75%); positive and negative predictive values were 85% (95% CI, 79%-90%) and 80% (95% CI, 68%-89%) respectively, based on the study prevalence of 69% of patients with PCP. Rates of abnormal lactate dehyrogenase levels did not differ significantly between those with and without PCP. CONCLUSIONS: Blood (1 → 3)-β-D-glucan is strongly correlated with HIV-related PCP. In some clinical centers, this may be a more sensitive test than the induced sputum examination and could reduce the need for both bronchoscopy and empirical therapy of PCP.
Authors: Kate Buchacz; Rose K Baker; Frank J Palella; Joan S Chmiel; Kenneth A Lichtenstein; Richard M Novak; Kathleen C Wood; John T Brooks Journal: AIDS Date: 2010-06-19 Impact factor: 4.177
Authors: J Torres; M Goldman; L J Wheat; X Tang; M S Bartlett; J W Smith; S D Allen; C H Lee Journal: Clin Infect Dis Date: 2000-01 Impact factor: 9.079
Authors: Philip M Grant; Lauren Komarow; Janet Andersen; Irini Sereti; Savita Pahwa; Michael M Lederman; Joseph Eron; Ian Sanne; William Powderly; Evelyn Hogg; Carol Suckow; Andrew Zolopa Journal: PLoS One Date: 2010-07-01 Impact factor: 3.240
Authors: Stefanie Desmet; Eric Van Wijngaerden; Johan Maertens; Jan Verhaegen; Eric Verbeken; Paul De Munter; Wouter Meersseman; Britt Van Meensel; Johan Van Eldere; Katrien Lagrou Journal: J Clin Microbiol Date: 2009-10-21 Impact factor: 5.948
Authors: Andrew Zolopa; Janet Andersen; William Powderly; Alejandro Sanchez; Ian Sanne; Carol Suckow; Evelyn Hogg; Lauren Komarow Journal: PLoS One Date: 2009-05-18 Impact factor: 3.240
Authors: George R Thompson; Derek J Bays; Suzanne M Johnson; Stuart H Cohen; Demosthenes Pappagianis; Malcolm A Finkelman Journal: J Clin Microbiol Date: 2012-06-12 Impact factor: 5.948
Authors: Sejal Morjaria; John Frame; Alexandra Franco-Garcia; Alexander Geyer; Mini Kamboj; N Esther Babady Journal: Clin Infect Dis Date: 2019-09-27 Impact factor: 9.079
Authors: Mohamed F Ali; Christopher B Driscoll; Paula R Walters; Andrew H Limper; Eva M Carmona Journal: J Immunol Date: 2015-10-30 Impact factor: 5.422
Authors: Michael J Linke; Alan Ashbaugh; Margaret S Collins; Keeley Lynch; Melanie T Cushion Journal: Infect Immun Date: 2013-01-14 Impact factor: 3.441